GTx - 48 Year Dividend Yield History | GTXI

Historical dividend payout and yield for GTx (GTXI) since 1971. The current TTM dividend payout for GTx (GTXI) as of February 20, 2019 is $0.00. The current dividend yield for GTx as of February 20, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.022B $0.000B
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $116.347B 12.98
Gilead Sciences (GILD) United States $86.362B 10.84
Bio-Techne Corp (TECH) United States $7.246B 48.82